Flagship launches Ring with $50M, new gene therapy vectors

Ring Therapeutics, the latest company to emerge from Flagship Pioneering, has a gene therapy platform that it thinks will solve the biggest problems with the modality: immunogenicity, tissue access and genomic integration.

With a $50 million initial investment, the company is creating a new type of viral vector based on a family of commensal human viruses dubbed anelloviruses, which naturally exist in most of the human population without any apparent health impacts...